Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-4525
Glas, M; Rasch, K; Wiewrodt, D; Weller, M; Herrlinger, U (2008). Procarbazine and CCNU as initial treatment in gliomatosis cerebri. Oncology, 75(3-4):182-185.
View at publisher
Background: Gliomatosis cerebri (GC) is a diffuse infiltrating glial tumor with involvement of at least 3 cerebral lobes. There are only few data on the efficacy of initial chemotherapy in patients with GC. Patients and Methods: In 3 neurooncological centers, patients with newly diagnosed GC who had received procarbazine (60 mg/m(2), days 8-21/56) and CCNU (110 mg/m(2), day 1/56) chemotherapy (PC) as initial treatment were analyzed for progression-free survival, overall survival and toxicity. Results: Twelve patients (median age 46 years, range 27-72) were analyzed. The median progression-free survival and the median overall survival were 16 and 37 months. Grade 3 or 4 hematotoxicity was observed in 3 of 12 patients (25%). Conclusions: These data support the efficacy of PC chemotherapy in newly diagnosed GC. Initial PC chemotherapy should be considered as a treatment option and evaluated in larger clinical trials.
107 downloads since deposited on 04 Nov 2008
24 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||04 Nov 2008 15:35|
|Last Modified:||27 Nov 2013 22:09|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page